ABSTRACT
OBJECTIVE: To investigate the expression of vascular endothelial growth factor (VEGF) and its significance in primary diffuse large B-cell lymphoma of the female genital system. METHODS: VEGF mRNA and expression of VEGF protein were detected by real-time fluorescence quantitative PCR method and immunohistochemistry, respecitvely. Microvessel density (MVD) was obtained after staining of microvessels using CD34 antibody. The relationship between the expression of VEGF and MVD, clinical features and prognosis of primary diffuse large B-cell lymphoma of the female genital system patients were analyzed. RESULTS: (1) Over expression of VEGF mRNA was found in 17/20 (85.0%) by real-time fluorescence quantitative PCR method and the tumor cells expressed VEGF protein in 48/56 (85.7%) by immunohistochemistry; (2) The expression of VEGF was positively correlated to the MVD of the tumor (r = 0.76, P = 0.0170); (VEGF expression was correlated to clinical stages, B symptom and the serum level of lactate dehydrogenase (LDH) (r = 0.77, P = 0.044; r = 0.58, P = 0.023; r = 0.69, P = 0.017); (4) Cox multivariate analysis demonstrated that the age of more than 60 years and the positive VEGF expression were independent prognostic factors (P < 0.05). CONCLUSION: VEGF was widely expressed in the tumor cells of primary diffuse large B-cell lymphoma of the female genital system and may be related to the clinical features and prognosis of primary diffuse large B-cell lymphoma of the female genital system patients.
Subject(s)
Genital Neoplasms, Female/metabolism , Lymphoma, Large B-Cell, Diffuse/metabolism , Vascular Endothelial Growth Factor A/metabolism , Adolescent , Adult , Aged , Female , Humans , Lymphoma, Large B-Cell, Diffuse/pathology , Middle Aged , Ovarian Neoplasms/metabolism , Prognosis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Uterine Cervical Neoplasms/metabolism , Vascular Endothelial Growth Factor A/genetics , Young AdultABSTRACT
OBJECTIVE: To observe the clinicopathologic manifestations and to investigate the clinicopathologic features and diagnosis of primary ovarian non-Hodgkin's lymphoma. METHODS: A retrospective study of clinicopathology was made for 15 cases of primary ovarian non-Hodgkin's lymphomas. The histological classifying was based on the WHO classification for tumors of hematopoietic and lymphoid tissues (2001). Immunophenotype analysis was made by SP method. RESULTS: This kind of tumor was accounted for 0.56% of all non-Hodgkin's lymphoma (NHL) received in the same period. In all 15 cases, the patients of stage III and IV were 12 (80%), and stage I and II were 3 cases (20%). Histological classification: all 15 cases (100%) were diffuse large B cell lymphoma (DLBCL), centroblast or immunoblast types. All patients had received operation; three of them also received chemotherapy of CHOP or COMP. The follow-up data was available for 4 cases, and all of them died within period of 21 days to 18 months. CONCLUSION: Primary ovarian non-Hodgkin's lymphoma is rare and the prognosis is usually poor. Establishment of the diagnosis is based on pathological biopsy and immunophenotype analysis. Owing to the diagnosis made usually after most cases operated, the surgical treatment is still the essential, and the chemotherapy and radiotherapy are also adjuvant for the tumor.
